Literature DB >> 30664104

Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated Clostridium difficile Infection in Children.

Zachary I Willis1, Maribeth R Nicholson2, Adam J Esbenshade3, Meng Xu4, James C Slaughter4, Debra L Friedman3, Kathryn M Edwards5, Maria C Di Pentima6.   

Abstract

Clostridium difficile infection (CDI) is common in pediatric oncology patients and is often associated with recurrences and complications. We hypothesized that higher intensity of chemotherapy would be associated with these outcomes. We conducted a retrospective cohort study including all cases of primary CDI in children with malignancy in our institution for over 7 years. Intensity of chemotherapy was measured by the Intensity of Treatment Rating Scale, third edition, ranging from level 1 (minimal) to 4 (highest). Outcomes included recurrence within both 56 and 180 days, CDI-associated complications, and primary treatment failure (PTF). Risk of recurrence was compared using Cox proportional hazards regression. Among 192 patients with CDI and malignancy, 122 met inclusion criteria. CDI recurred in 27% (31/115) of patients followed for 56 days and 46% (48/104) of patients followed for 180 days. Fourteen patients (11.4%) had a CDI-associated complication, including 4 intensive care unit admissions and 3 surgical procedures, but no deaths. Ten patients (8.2%) had PTF. Although PTF and severe complications were infrequent, recurrence was common in our cohort. None of these outcomes were associated with level of treatment intensity. More research is required to assess oncologic and nononcologic risk factors for CDI recurrence, PTF, and severe CDI-associated complications.

Entities:  

Mesh:

Year:  2019        PMID: 30664104      PMCID: PMC6635100          DOI: 10.1097/MPH.0000000000001411

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  21 in total

1.  Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.

Authors:  Teena Chopra; Pranatharthi Chandrasekar; Hossein Salimnia; Lance K Heilbrun; Daryn Smith; George J Alangaden
Journal:  Clin Transplant       Date:  2010-10-25       Impact factor: 2.863

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Clostridium difficile infection among children with cancer.

Authors:  Eric Tai; Lisa C Richardson; Julie Townsend; Elizabeth Howard; L Clifford Mcdonald
Journal:  Pediatr Infect Dis J       Date:  2011-07       Impact factor: 2.129

Review 4.  Clostridium difficile infection in infants and children.

Authors:  Gordon E Schutze; Rodney E Willoughby
Journal:  Pediatrics       Date:  2012-12-31       Impact factor: 7.124

5.  A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment.

Authors:  Anne E Kazak; Matthew C Hocking; Richard F Ittenbach; Anna T Meadows; Wendy Hobbie; Branlyn Werba DeRosa; Ann Leahey; Leslie Kersun; Anne Reilly
Journal:  Pediatr Blood Cancer       Date:  2011-08-19       Impact factor: 3.167

6.  Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.

Authors:  Lorraine Kyne; Stavros Sougioultzis; Lynne V McFarland; Ciarán P Kelly
Journal:  Infect Control Hosp Epidemiol       Date:  2002-11       Impact factor: 3.254

7.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

Review 8.  Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients.

Authors:  Teena Chopra; George J Alangaden; Pranatharthi Chandrasekar
Journal:  Expert Rev Anti Infect Ther       Date:  2010-10       Impact factor: 5.091

9.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

10.  Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer.

Authors:  Peter de Blank; Theoklis Zaoutis; Brian Fisher; Andrea Troxel; Jason Kim; Richard Aplenc
Journal:  J Pediatr       Date:  2013-03-08       Impact factor: 4.406

View more
  1 in total

1.  Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.

Authors:  Shane J Cross; Theodore H Morton; Joshua Wolf
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 3.164

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.